The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Optimizing first line treatment in metastatic pancreatic cancer
Current treatment options for metastatic pancreatic cancer in the first-line setting include gemcitabine with nab-paclitaxel, FOLFIRINOX, or NALIRIFOX. Benedikt Westphalen, MD, PhD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, discusses the trial design of the Phase II FOOTPATH trial (NCT03487016) of deescalated FOLFIRINOX to FOLFIRI, based on the NAPOLI regimen, versus a sequential FOLFIRINOX regimen in patients with metastatic pancreatic cancer (mPDAC). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
